BioNexus Gene Lab (BGLC) Competitors

$1.98 0.00 (0.00%)

Closing price 03:56 PM Eastern

Extended Trading

$1.98 0.00 (0.00%)

As of 05:23 PM Eastern

BGLC vs. BMGL, ADVB, ACON, MRAI, and BRTX

Should you buy BioNexus Gene Lab stock or one of its competitors? MarketBeat compares BioNexus Gene Lab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioNexus Gene Lab include Basel Medical Group (BMGL), Advanced Biomed (ADVB), Aclarion (ACON), Marpai (MRAI), and Biorestorative Therapies (BRTX). These companies are all part of the "healthcare" industry.

How does BioNexus Gene Lab compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Basel Medical Group has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.09, meaning that its share price is 309% more volatile than the broader market.

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -40.19%. Basel Medical Group's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
BioNexus Gene Lab	-40.19%	-38.85%	-33.36%

BioNexus Gene Lab has lower revenue, but higher earnings than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.48	-$9.50M	N/A	N/A
BioNexus Gene Lab	$7.43M	0.64	-$2.98M	-$1.28	N/A

In the previous week, Basel Medical Group had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 2 mentions for Basel Medical Group and 1 mentions for BioNexus Gene Lab. Basel Medical Group's average media sentiment score of 1.31 beat BioNexus Gene Lab's score of 0.93 indicating that Basel Medical Group is being referred to more favorably in the media.

Company	Overall Sentiment
Basel Medical Group	Positive
BioNexus Gene Lab	Positive

Summary

Basel Medical Group beats BioNexus Gene Lab on 7 of the 11 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Advanced Biomed?

Advanced Biomed (NASDAQ:ADVB) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Advanced Biomed has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, BioNexus Gene Lab has a beta of 4.09, meaning that its share price is 309% more volatile than the broader market.

Advanced Biomed has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -40.19%. Advanced Biomed's return on equity of 92.11% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Biomed	N/A	92.11%	58.03%
BioNexus Gene Lab	-40.19%	-38.85%	-33.36%

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 34.4% of Advanced Biomed shares are owned by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Advanced Biomed had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 2 mentions for Advanced Biomed and 1 mentions for BioNexus Gene Lab. Advanced Biomed's average media sentiment score of 1.21 beat BioNexus Gene Lab's score of 0.93 indicating that Advanced Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Advanced Biomed	Positive
BioNexus Gene Lab	Positive

BioNexus Gene Lab has higher revenue and earnings than Advanced Biomed. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Biomed	N/A	N/A	-$3.26M	$3.80	1.17
BioNexus Gene Lab	$7.43M	0.64	-$2.98M	-$1.28	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Advanced Biomed beats BioNexus Gene Lab on 8 of the 12 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Aclarion?

BioNexus Gene Lab (NASDAQ:BGLC) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by insiders. Comparatively, 0.8% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioNexus Gene Lab has a beta of 4.09, indicating that its stock price is 309% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

BioNexus Gene Lab has higher revenue and earnings than Aclarion. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.64	-$2.98M	-$1.28	N/A
Aclarion	$80K	99.02	-$7.23M	-$17.01	N/A

BioNexus Gene Lab has a net margin of -40.19% compared to Aclarion's net margin of -10,320.51%. BioNexus Gene Lab's return on equity of -38.85% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-40.19%	-38.85%	-33.36%
Aclarion	-10,320.51%	-61.10%	-58.01%

In the previous week, Aclarion had 8 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 9 mentions for Aclarion and 1 mentions for BioNexus Gene Lab. Aclarion's average media sentiment score of 1.05 beat BioNexus Gene Lab's score of 0.93 indicating that Aclarion is being referred to more favorably in the news media.

Company	Overall Sentiment
BioNexus Gene Lab	Positive
Aclarion	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioNexus Gene Lab beats Aclarion on 8 of the 13 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Marpai?

BioNexus Gene Lab (NASDAQ:BGLC) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

In the previous week, Marpai had 1 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 2 mentions for Marpai and 1 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 0.93 beat Marpai's score of 0.00 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company	Overall Sentiment
BioNexus Gene Lab	Positive
Marpai	Neutral

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by insiders. Comparatively, 46.1% of Marpai shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioNexus Gene Lab has a beta of 4.09, meaning that its stock price is 309% more volatile than the broader market. Comparatively, Marpai has a beta of 4.38, meaning that its stock price is 338% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BioNexus Gene Lab has higher earnings, but lower revenue than Marpai. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.64	-$2.98M	-$1.28	N/A
Marpai	$34.87M	0.22	-$28.75M	-$0.95	N/A

BioNexus Gene Lab has a net margin of -40.19% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-40.19%	-38.85%	-33.36%
Marpai	-85.70%	N/A	-100.23%

Summary

Marpai beats BioNexus Gene Lab on 8 of the 14 factors compared between the two stocks.

How does BioNexus Gene Lab compare to Biorestorative Therapies?

BioNexus Gene Lab (NASDAQ:BGLC) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioNexus Gene Lab has a beta of 4.09, indicating that its share price is 309% more volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioNexus Gene Lab has a net margin of -40.19% compared to Biorestorative Therapies' net margin of -3,956.11%. BioNexus Gene Lab's return on equity of -38.85% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-40.19%	-38.85%	-33.36%
Biorestorative Therapies	-3,956.11%	-430.91%	-203.61%

In the previous week, Biorestorative Therapies had 3 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 4 mentions for Biorestorative Therapies and 1 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 0.93 beat Biorestorative Therapies' score of 0.47 indicating that BioNexus Gene Lab is being referred to more favorably in the media.

Company	Overall Sentiment
BioNexus Gene Lab	Positive
Biorestorative Therapies	Neutral

BioNexus Gene Lab has higher revenue and earnings than Biorestorative Therapies. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.64	-$2.98M	-$1.28	N/A
Biorestorative Therapies	$360K	13.37	-$14.24M	-$1.59	N/A

Summary

BioNexus Gene Lab beats Biorestorative Therapies on 8 of the 13 factors compared between the two stocks.

Get BioNexus Gene Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGLC vs. The Competition

Export

Metric	BioNexus Gene Lab	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.77M	$8.35B	$6.34B	$12.38B
Dividend Yield	N/A	3.03%	2.80%	5.35%
P/E Ratio	-1.54	16.62	17.79	23.07
Price / Sales	0.64	16.95	549.57	79.28
Price / Cash	N/A	81.29	43.26	56.33
Price / Book	0.55	5.65	9.93	6.96
Net Income	-$2.98M	$183.43M	$3.55B	$333.52M
7 Day Performance	-5.91%	0.14%	-0.33%	0.45%
1 Month Performance	-9.98%	5.21%	1.34%	4.06%
1 Year Performance	-33.50%	4.75%	41.10%	36.24%

BioNexus Gene Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGLC BioNexus Gene Lab	0.407 of 5 stars	$1.98 flat	N/A	-35.2%	$4.77M	$7.43M	N/A	30	High Trading Volume
BMGL Basel Medical Group	0.5887 of 5 stars	$0.70 +14.8%	N/A	-83.4%	$11.40M	$11.32M	N/A	36	High Trading Volume
ADVB Advanced Biomed	1.2578 of 5 stars	$6.78 -1.2%	N/A	N/A	$9.36M	N/A	1.78	40	Positive News Short Interest Decrease Gap Down
ACON Aclarion	1.2188 of 5 stars	$3.28 +2.5%	N/A	-55.2%	$7.88M	$75.73K	N/A	7	News Coverage Earnings Report Upcoming Earnings
MRAI Marpai	N/A	$0.27 -0.3%	N/A	-83.1%	$6.84M	$34.87M	N/A	150	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGLC) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. BMGL, ADVB, ACON, MRAI, and BRTX

How does BioNexus Gene Lab compare to Basel Medical Group?

Summary

How does BioNexus Gene Lab compare to Advanced Biomed?

Summary

How does BioNexus Gene Lab compare to Aclarion?

Summary

How does BioNexus Gene Lab compare to Marpai?

Summary

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNexus Gene Lab (BGLC) Competitors

BGLC vs. BMGL, ADVB, ACON, MRAI, and BRTX

How does BioNexus Gene Lab compare to Basel Medical Group?

Which has more risk and volatility, BMGL or BGLC?

Do institutionals & insiders hold more shares of BMGL or BGLC?

Do analysts recommend BMGL or BGLC?

Is BMGL or BGLC more profitable?

Which has preferable valuation and earnings, BMGL or BGLC?

Does the media favor BMGL or BGLC?

Summary

How does BioNexus Gene Lab compare to Advanced Biomed?

Which has more risk and volatility, ADVB or BGLC?

Is ADVB or BGLC more profitable?

Do institutionals & insiders hold more shares of ADVB or BGLC?

Does the media favor ADVB or BGLC?

Which has preferable valuation and earnings, ADVB or BGLC?

Do analysts recommend ADVB or BGLC?

Summary

How does BioNexus Gene Lab compare to Aclarion?

Do insiders & institutionals hold more shares of BGLC or ACON?

Which has more risk and volatility, BGLC or ACON?

Which has higher earnings and valuation, BGLC or ACON?

Is BGLC or ACON more profitable?

Does the media refer more to BGLC or ACON?

Do analysts prefer BGLC or ACON?

Summary

How does BioNexus Gene Lab compare to Marpai?

Does the media refer more to BGLC or MRAI?

Do institutionals and insiders believe in BGLC or MRAI?

Which has more risk and volatility, BGLC or MRAI?

Do analysts rate BGLC or MRAI?

Which has higher valuation & earnings, BGLC or MRAI?

Is BGLC or MRAI more profitable?

Summary

How does BioNexus Gene Lab compare to Biorestorative Therapies?

Do insiders & institutionals believe in BGLC or BRTX?

Which has more volatility & risk, BGLC or BRTX?

Do analysts rate BGLC or BRTX?

Is BGLC or BRTX more profitable?

Does the media refer more to BGLC or BRTX?

Which has better valuation and earnings, BGLC or BRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGLC vs. The Competition

BioNexus Gene Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools